Evidence map›Paper›PMID 35764258›Full record

ArticleClinical immunology (Orlando, Fla.)2022

High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19.

Mirko Scordio, Federica Frasca, Letizia Santinelli, Leonardo Sorrentino, Alessandra Pierangeli, Ombretta Turriziani, Claudio M Mastroianni, Guido Antonelli, Raphael P Viscidi, Gabriella d'Ettorre and 1 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Mirko ScordioDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: mirko.scordio@uniroma1.it.
Federica FrascaDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: federica.frasca@uniroma1.it.
Letizia SantinelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: letizia.santinelli@uniroma1.it.
Leonardo SorrentinoDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: leonardo.sorrentino@uniroma1.it.
Alessandra PierangeliDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: alessandra.pierangeli@uniroma1.it.
Ombretta TurrizianiDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy; Microbiology and Virology Unit, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. Electronic address: ombretta.turriziani@uniroma1.it.
Claudio M MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: claudio.mastroianni@uniroma1.it.
Guido AntonelliDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy; Microbiology and Virology Unit, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. Electronic address: guido.antonelli@uniroma1.it.
Raphael P ViscidiDepartment of Pediatrics, Johns Hopkins University School of Medicine, 1800 Orleans Street Baltimore, MD, United States. Electronic address: rviscid1@jhmi.edu.
Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: gabriella.dettorre@uniroma1.it.
Carolina ScagnolariDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: carolina.scagnolari@uniroma1.it.
Policlinico Umberto I · ITSapienza University of Rome · ITJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.

Indexed as

COVID-19HIV-1Interferon Type IAntibodies, NeutralizingAntibodies, ViralFemaleHumansInterferon-alphaMaleSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralInterferon-alphaInterferon Type IHIV-1HIV-1 and SARS-CoV-2 co-infectionInterferonISGsNeutralizing antibodiesSARS-CoV-2

Identifiers

PMID35764258
PMCPMC9233547
OpenAlexW4283521060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.